**Question:** Screening of prostate CA is best done by

A. Digital Rectal Examination (DRE)
B. Prostate Specific Antigen (PSA) test
C. Transrectal Ultrasound (TRUS)
D. Transrectal Ultrasound-guided biopsy (TRUSBx)

**Correct Answer:** D. Transrectal Ultrasound-guided biopsy (TRUSBx)

**Core Concept:** Prostate cancer (PCa) is a prevalent cancer type in males, and early detection plays a crucial role in its management. Traditional methods like Digital Rectal Examination (DRE) and Prostate Specific Antigen (PSA) test have limitations, prompting the need for advanced techniques.

**Why the Correct Answer is Right:** Transrectal Ultrasound-guided biopsy (TRUSBx) is the most suitable method for prostate cancer screening among the provided options. TRUSBx combines the advantages of ultrasound imaging with the capability of obtaining prostate tissue samples, enabling accurate identification of cancerous lesions.

**Why Each Wrong Option is Incorrect:**

A. Digital Rectal Examination (DRE) is a physical examination technique used to assess the prostate for abnormalities. However, it has limitations:
- Insufficient sensitivity: DRE may miss small or localized tumors.
- Patient positioning: Difficulty in performing DRE in patients with rectal disorders or those taking laxatives.

B. Prostate Specific Antigen (PSA) test is a blood test used to measure the levels of prostate specific antigen (PSA), a protein produced by the prostate gland. While PSA is useful in monitoring treatment response and detecting recurrence, it has limitations:
- False positives: Elevated PSA levels can be caused by non-cancerous conditions like inflammation or prostatitis, leading to unnecessary biopsies and treatments.
- False negatives: Low PSA levels do not rule out prostate cancer, as PSA levels can be normal in early-stage cancer patients.

C. Transrectal Ultrasound (TRUS) is a diagnostic imaging technique that uses sound waves to visualize the prostate and surrounding structures. Although TRUS plays a crucial role in guiding biopsy procedures, it is not sufficient for screening purposes:
- Limited sensitivity: TRUS alone may not detect small or localized tumors.
- Patient anatomy: Difficulty in visualizing the prostate's peripheral zone, which is the most common site for prostate cancer.

D. TRUSBx is a procedure where TRUS is used to guide the biopsy of the prostate. By combining the advantages of TRUS with the ability to obtain prostate tissue samples, TRUSBx overcomes the limitations of DRE, PSA, and TRUS alone:
- Increased accuracy: TRUSBx improves the chances of detecting prostate cancer by utilizing TRUS guidance.
- Enhanced sensitivity: TRUSBx enhances the ability to obtain tissue samples from the peripheral zone, which is the most common site for prostate cancer.

**Clinical Pearl**: Screening for prostate cancer should be conducted in a multi-step approach involving Digital R